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ABSTRACT    24 
Purpose: We aim to provide a comprehensive overview of the role of the vagina as a route for drug 25 
delivery and absorption, with a particular focus on the use of vaginal hormonal compounds for the 26 
treatment of deep infiltrating symptomatic endometriosis. 27 
Methods: A MEDLINE search through PubMed was performed to identify all published studies in 28 
English language on vaginal hormonal treatments for symptomatic endometriosis. 29 
Results: Main advantages of the vaginal route include avoidance of the hepatic-first pass metabolic 30 
effect, the possibility of using lower therapeutic dosages, and the reduction of side effects compared 31 
with the oral administration. Studies on endometriosis treatment mainly focused on the use of 32 
vaginal danazol (n=6) and the contraceptive vaginal ring (n=2). One pilot study evaluated the 33 
efficacy of vaginal anastrozole in women with rectovaginal endometriosis. Most investigations 34 
evaluated the vaginal use of hormonal agents in women with deep infiltrating 35 
endometriosis/rectovaginal endometriosis. Overall, a substantial amelioration of pelvic pain 36 
symptoms associated with endometriosis was observed, particularly of dysmenorrhea. A significant 37 
reduction in rectovaginal endometriotic nodule dimensions measured at ultrasound examination was 38 
detected by some but not all authors. 39 
Conclusions: The vaginal route represents a scarcely explored modality for drug administration. 40 
High local hormonal concentrations might achieve a greater effect on endometriotic lesions 41 
compared with alternative routes. Future studies should focus on the use of the vagina for delivering 42 
target therapies particularly in patients with deeply infiltrating rectovaginal lesions. 43 
KEYWORDS: Intravaginal administration; vaginal ring; endometriosis; aromatase inhibitors; 44 
danazol; contraceptive vaginal ring 45 
 46 
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INTRODUCTION 47 
In the last decades, technological innovations in drug delivery have led to a wider range of sites for 48 
drug administration. Historically, the oral route represents the most frequently adopted one. 49 
However, another scarcely explored way of drug delivery is the vaginal route; although a large 50 
body of evidence proves the ability of this organ to absorb a wide variety of medication [1].   51 
The first published reports of drugs administered intravaginally are dated 1918, when Macht 52 
reported the absorption of morphine, potassium iodide and atropine [2]. Since then the vaginal route 53 
has been adopted for numerous, chemically different, compounds, such as misoprostol, 54 
bromocriptine, indomethacin, antimicrobials, and various steroidal hormones including estrogens, 55 
progestogens and androgens [1, 3].    56 
 An important field of application for intravaginal therapies could be endometriosis; in fact, 57 
in the past years, some authors have evaluated the efficacy of various vaginal hormonal compounds 58 
for the treatment of rectovaginal endometriosis with promising results [4-6]. 59 
Endometriosis is an estrogen-dependent chronic inflammatory disorder that requires a life-60 
long management plan. Some authors suggest that women with endometriosis should no longer be 61 
evaluated as a single and unique population [4]. In this optic, each woman should have a tailored 62 
approach based on her main disabling symptom and the type of lesion [4]. In particular, deep 63 
infiltrating endometriosis (DIE) represents the truly severe endometriotic disease [7]. DIE is a form 64 
of endometriosis characteristically related to marked proliferation of smooth muscle cells and 65 
fibrosis [8]. Deep lesions could infiltrate the muscular layer of different hollow organs, such as 66 
vagina, bowel, and bladder. Patients with DIE are usually the ones complaining most for pain and 67 
with the greatest alteration on the quality of life (QoL).  68 
Long-term adherence to treatment is pivotal to ensure an effective clinical management 69 
[4,9]. The rationale of the pharmacological therapy for symptomatic endometriosis is the 70 
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establishment of a hypo-estrogenic milieu, generally achievable through the use of hormonal 71 
therapies such as, for instance, estrogen-progestins and progestins [4]. These compounds could be 72 
administered orally, vaginally, intra-uterine, subcutaneously or intramuscularly [4].    73 
In this narrative review, we aimed to provide a broad overview on the role of the vagina as a 74 
route for drug delivery and absorption, with a specific focus on the use of vaginal hormonal 75 
compounds for the treatment of deep infiltrating symptomatic endometriosis. 76 
MATERIALS AND METHODS 77 
For this review, the best quality evidence was selected with preference given to the most 78 
recent and definitive original articles and reviews. Information was identified by searches of 79 
Pubmed/MEDLINE and references from relevant articles, using combinations of MESH terms 80 
“intravaginal administration”, “pharmacodynamics”, “endometriosis”, “deep infiltrating 81 
endometriosis”, “vaginal danazol”, “contraceptive vaginal ring”, “vaginal ring”, and “aromatase 82 
inhibitors”. The search was limited to peer-reviewed, full-text articles in the English language. For 83 
most issues, papers published between March 1990 and December 2016 were considered. No 84 
attempt was made to find unpublished studies. Since only published data were considered, the 85 
current research project was exempt from Institutional Review Board approval. 86 
RESULTS 87 
➢ Role of the vagina as a route for drug delivery and absorption  88 
The vagina is a collapsed organ, in which the surface absorption area is augmented by the presence 89 
of numerous rugae and could reach a maximum of 95 cm2 in standard conditions [10].   90 
  One of the peculiar aspects of the vagina is represented by its vascular supply that comprises 91 
a complex network of veins. In particular, the different portions of the vagina are drained by various 92 
venous systems influencing drug absorption depending on the level at which the compound has 93 
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been introduced [10]. The uterine and ovarian plexus are linked to the venous return of the superior 94 
part of the vagina, and they drain directly into the internal iliac vein, by-passing the hepatic portal 95 
system. In particular, a pharmacological compound administered in the superior part of the vagina 96 
has a specific affinity for the uterine tissues, especially for the endometrium, due to the extensive 97 
vascular connections between these two organs. This phenomenon, given its similarity with the 98 
hepatic-first pass metabolism secondary to the oral administration, has been termed “uterine first-99 
pass effect” [11]. Instead, the inferior part of the vagina is connected to the hemorrhoidal and 100 
pudenda internal plexus, which leads to the portal system and is subject to the metabolizing action 101 
of the liver [3].  102 
 In general, drug absorption is a passive process regulated by different factors such as 103 
molecular weight, liposolubility, constancy of diffusion, time, and surface of diffusion [10]. In 104 
addition, vaginal drug absorption is also influenced by some physiological factors, including age, 105 
pregnancy, hormone status, and pH changes. The modifications of this latter element are secondary 106 
to numerous variables such as bacterial colonization, semen, menstruation, and estrogen status. 107 
Vaginal absorption of a drug could be impacted by the presence of a larger volume of vaginal fluids 108 
that can favor a more rapid and efficient dissolution of compounds characterized by low 109 
hydrosolubility but, at the same time, can raise the possibilities of a drug to be ejected due to 110 
gravity. Moreover, the presence of cervical mucus with high viscosity could represent an obstacle to 111 
drug absorption [12].   112 
Another factor to keep in mind when prescribing intravaginal therapies is the age of the 113 
patient; in fact, in post-menopausal women, the thickness of the vaginal walls is reduced, and the 114 
absorption of steroids is higher than in fertile women [13]. In addition, changes in hormone levels, 115 
especially estrogen, during the menstrual cycle, cause alterations in the thickness of the epithelial 116 
cell layer, width of intercellular channels, pH, and secretions, with subsequent variations in vaginal 117 
drug absorption [10,14]. Estrogenization of the vaginal mucosa improves absorption of hormones 118 
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through the vaginal wall [10,15]. Finally, the formulation and the carrier also influence the 119 
absorption rate. For example, creams’ absorption is higher compared to rings and tablets [10].  120 
One of the most studied vaginal pharmacological compounds is represented by the vaginal 121 
contraceptive ring (CVR) (ethinyl estradiol (EE) 15 μg + etonogestrel (ENG) 120 μg).  Numerous 122 
studies have compared the pharmacokinetics of the steroids released by the CVR with those 123 
discharged by various combined oral contraceptive (COC) [16-18]. Timmer and Mulders [17] 124 
performed a randomized crossover study on 16 healthy women demonstrating that maximal serum 125 
concentration (Cmax) of ENG and EE obtained with the vaginal contraceptive ring were 40% and 126 
30% inferior of those gained with a COC containing 150 μg of desogestrel (DSG) and 30 μg of EE. 127 
In the same study group, absolute bioavailability was comparable for EE but higher for ENG with 128 
the CVR compared with the COC (103% vs 79%) [17].  129 
A randomized open-label study [18], performed on 24 women, compared different serum EE 130 
levels subsequent to the use of the CVR, of the transdermal patch or of a COC (EE 30 μg + 131 
levonorgestrel (LNG) 150 μg). Cmax of EE for the ring, the patch, and the COC were 37.1 pg/ml, 132 
105 pg/ml, and 168 pg/ml, respectively. In addition, analysis of area under the EE concentration-133 
versus-time curve (AUC) during 21 days of treatment showed that exposure to EE in the CVR 134 
group was 3.4 times lower than in the patch group and 2.1 times lower than in the COC group. 135 
These findings suggest that suppression of ovulation with the CVR is comparable to that reached 136 
with COCs but with lower circulating levels of EE.  137 
Moreover, Roumen et al. [19] compared the uterine concentrations of EE and ENG after use 138 
of CVR and a COC (EE 20 μg + DSG 150 μg). In both groups, concentration of ENG and EE were 139 
comparable in uterine samples of the myometrium and cervical region. However, unexpectedly, in 140 
women treated with the CVR concentration of both ENG and EE were significantly lower in tissue 141 
samples from the endometrium. Finally, Dogterom et al. [20] performed a pharmacokinetic study in 142 
order to assess the potential interaction of a concomitant treatment with oral antibiotics (amoxicillin 143 
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and doxycycline). No differences in ENG or EE serum concentrations were identified between 144 
women using vaginal contraceptive ring alone versus those receiving the ring plus either of the 145 
antibiotics. Conversely, co-administration of vaginal anti-mycotic resulted in a slight rise in 146 
systemic exposure of both ENG and EE, in particular with suppositories antifungal formulations 147 
[21]. 148 
Pharmacokinetic studies on progestogen only CVR demonstrated a good correlation 149 
between in vitro and in vivo release rates of LNG [22]. Serum levels reached the peak concentration 150 
2 hours after the insertion of the ring, after which levels diminished at a rate of 0.2%/day during 90 151 
days of continuous use. Other pharmacokinetic studies on various progestogen-releasing vaginal 152 
ring have been conducted. As an example, Landgren et al. [23, 24] evaluated two types of vaginal 153 
ring releasing norethisterone (NET) at a rate of 50 μg/daily and 200 μg /daily. The ring containing 154 
the lower dose of NET did not inhibit ovulation with consequent high pregnancy rate, whereas 155 
those releasing the higher dose of NET displayed a strong ovulation-inhibiting effect but showed a 156 
high frequency of unscheduled bleeding.  157 
➢ Vaginal therapies for the treatment of symptomatic deep infiltrating endometriosis 158 
The intravaginal route has been underused for the treatment of endometriosis (Table 1). The 159 
majority of the evidence regarding the vaginal route for the management of endometriosis are 160 
derived from the use of danazol.  161 
Danazol is a synthetic derivative of 17α-ethyniltestosterone with mild androgenic activity. 162 
Oral danazol has been widely adopted in the treatment of endometriosis at the daily dosage of 400-163 
800 mg, resulting in high serum concentration of the compound, which may elicit androgenic 164 
adverse effects, such as acne, hirsutism, weight gain, deepening of voice pitch, and alteration of the 165 
blood lipid profile [32,33]. Oral danazol acts on endometriotic lesions at two levels: firstly, danazol 166 
shows inhibitory effect on the hypothalamic-pituitary-ovarian axis; secondly, danazol can work 167 
   
 
Buggio et al., 9 
directly on endometriotic tissues through the inhibition of aromatase activity, reducing 168 
inflammation and the production of angiogenic factors, making endometriotic lesions inactive and 169 
atrophic [34]. However, danazol used orally for an extended period is not advisable, due to the 170 
important androgenic side effects, and for this reason different study groups have assessed its 171 
vaginal use (Table 1).  172 
 First, Igarashi et al. [25,26] evaluated the efficacy of a danazol-loaded vaginal ring in 173 
women with endometriosis. In the first study [25], the vaginal ring (releasing 95 mg of danazol per 174 
day) was used in 35 infertile women with endometriosis. Authors found a substantial amelioration 175 
in both dysmenorrhea and a decrease in the extent of pelvic endometriosis. In addition, as vaginal 176 
danazol did not inhibit ovulation, 13 patients conceived while using the vaginal ring. This point is 177 
particular concerning due to the potential teratogenic effects of this drug [35].  In fact, as reported in 178 
a previous retrospective review [35] on 129 women exposed to danazol during pregnancy, only 37 179 
delivered a normal male and 24 a non-virilized female, whereas, 23 women gave birth to a virilized 180 
female. All the abnormalities have been reported in those patients who continued danazol 181 
administration after the 8th week of gestation. In this view, danazol should remain contraindicated in 182 
pregnancy and a careful contraceptive advice to patients under danazol therapy should be given. 183 
In the second study [26], danazol was administered using a vaginal ring drug delivery 184 
system containing 1500 mg of danazol. Igarashi et al. [26] enrolled 56 infertile women with 185 
endometriosis, 42 with DIE, and 14 with ovarian endometriomas.  All the enrolled patients showed 186 
normal menstruation pattern and basal body temperature curves; in addition, 39 of them conceived 187 
during the study period, and none of the female infants born presented signs of masculinization. 188 
Serum levels of danazol remained undetectable. The effectiveness on pain symptoms differed in the 189 
two groups, in fact, dysmenorrhea disappeared in 76% (32/42) of the patients with DIE, but only in 190 
50% (7/14) in the group with ovarian endometriomas. In addition, also at transvaginal ultrasound 191 
the size of the ovarian cysts, conversely to endometriotic deep nodules, remained unchanged in 192 
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almost 80% of cases (11/14). Moreover, one woman out of four (2/8) conceived in the ovarian 193 
endometriotic cyst group, compared to one out of two (17/31) in the DIE group. A plausible 194 
explanation for this different outcome in the two study groups could be attributed to the proximity 195 
of deep endometriotic lesions to the site of action of the vaginal ring. In this way, the drug released 196 
from the vaginal ring should ideally reach higher concentrations in the vaginal endometriotic lesion.  197 
 Razzi et al. [27] treated 21 symptomatic patients with DIE with low dose vaginal danazol 198 
(200 mg/d) for 12 months. Dysmenorrhea and dyspareunia were relieved in 19 out of the 21 women 199 
and were improved in the remainders. Relief from dyschezia was also observed. At ultrasound 200 
examination, a reduction of the volume of the rectovaginal nodule was demonstrated (from 3.11.2 201 
mL to 1.20.8 mL). Moreover, the vaginal use did not alter metabolic or thrombophilic parameters, 202 
and the main reported side effect was a vaginal irritation during the first month of treatment in only 203 
four cases. These promising results were similar to those obtained by Bhattacharya et al. [29], who 204 
adopted in 21 patients with severe endometriosis (stage IV), for a total treatment period of six 205 
months, the same vaginal dosage of danazol.  206 
 In 2011, Ferrero et al. [30], evaluated the effectiveness of therapy with very low-dose of 207 
vaginal danazol (100 mg/d) in patients with rectovaginal endometriosis and persistent pain 208 
symptoms refractory to the use of a levonorgestrel-releasing intrauterine device (LNG-IUD). 15 209 
women were enrolled for the study, and the daily administration of danazol lasted six months. At 210 
the end of the study period, the satisfaction rate associated with the treatment was 80%. In addition, 211 
the volume of the rectovaginal plaque decreased during treatment (from 2.30.9 cm3 to 1.70.8 212 
cm3). Side effects were minimal and well-tolerated, the most frequently reported was acne (n = 4).  213 
 The above-mentioned studies confirm the potential beneficial role of vaginal danazol in the 214 
treatment of women with endometriosis, in particular in those with deep infiltrating and vaginal 215 
localizations. Contrarily to oral administration, vaginally administered danazol showed limited 216 
androgenic side effects, and its serum levels remained low or undetectable. These results are 217 
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consistent with those of Mizutani et al. [36], who demonstrated that danazol concentration in the 218 
ovary and uterus after daily vaginal administration of 100 mg of danazol were analogous to those 219 
reached after oral administration of 400 mg, and, at the same time, serum level after daily 220 
intravaginal danazol use was less than 1/20 of that after oral administration.   221 
  Another vaginally administered drug that has been evaluated for the treatment of 222 
endometriosis is an estrogen-progestogen contraceptive ring [5,31] (Table 1). In 2010, Vercellini et 223 
al. [5], performed a patient preference trial on 207 women with recurrent moderate or severe pelvic 224 
pain after conservative surgery for symptomatic endometriosis, comparing the CVR (EE 15 μg + 225 
ENG 120 μg) and a transdermal patch (EE 20 μg + norelgestromin 150 μg). A total of 123 (59%) 226 
women preferred the CVR, whereas 84 (41%) chose the patch. Both treatments were administered 227 
continuously for 12 months. Fifty-nine (28%) patients with rectovaginal endometriosis were 228 
included in the study group. The rate of withdrawal was high in both group, 36% in the CVR group 229 
and 61% in the transdermal patch group. Bleeding control was suboptimal with both delivery 230 
systems, in fact, by the end of the study period 46% of the patients who chose the ring and 42% of 231 
those who preferred the patch changed from continuous to cyclic use. Pelvic pain symptoms were 232 
reduced in both groups. In particular, the CVR performed better than the patch regarding 233 
dysmenorrhea relief in patients with rectovaginal endometriotic lesions. A considerable 234 
amelioration of deep dyspareunia was also obtained. No significant major adverse event was 235 
recorded. At the end of study, 71% of the patients who have chosen the CVR declared to be 236 
satisfied with the treatment, whereas the percentage of satisfied women dropped to 48% in the patch 237 
group. In the sub-group of women with rectovaginal lesions, the percentage of satisfied women was 238 
higher in both groups: 79% in the CVR group and 57% in patients treated with the patch.  239 
 A second patient preference trial [31] compared the CVR, administered cyclically, to the 240 
desogestrel-only contraceptive pill (75 μg/d) for the treatment of symptomatic patients with 241 
rectovaginal endometriosis. The duration of the treatment was 12 months; 60 women chose the 242 
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progestin-only pill and 83 the CVR. At the end of the study, the rate of satisfied women was higher 243 
in the group treated with desogestrel-only pill (61.7% vs. 36.1%). The discontinuation rate and the 244 
reduction in volume of rectovaginal nodules were similar in the two study groups. Gastrointestinal 245 
symptoms, chronic pelvic pain and deep dyspareunia were improved more in the progestin-only pill 246 
than in CVR group.  247 
The potential beneficial role of vaginally administered aromatase inhibitors has been 248 
evaluated in a pilot study [6] on ten symptomatic patients with histologically confirmed 249 
rectovaginal endometriosis. Women received 0.25 mg/d of vaginal anastrozole for 6 months. The 250 
preliminary results were encouraging and patients reported an improvement of dysmenorrhea and 251 
QoL. However, chronic pelvic pain, dyspareunia as well as rectovaginal lesion size remained 252 
unchanged. The dual energy absorptiometry (DEXA) scans, performed before the initiation of the 253 
study and within one month after the end of the treatment, show no change in bone mineral density. 254 
Serum hormonal levels were repeatedly measured during the study period and within one month 255 
after the completion of the treatment. No statistically significant differences were observed in 256 
values for gonadotropins FSH and LH or for P and E2. In women with endometriosis the inhibition 257 
of the hypothalamic-pituitary-ovarian axis is of fundamental importance. Therefore, as suggested by 258 
Hefler et al. [6], a combined therapy with a hormonal drug capable of inhibit ovulation should be 259 
proposed.  260 
 Recently, a vaginal ring containing a combination of anastrozole (ATZ) and the progestin 261 
LNG has been developed for the treatment of endometriosis and tested in healthy cycling female 262 
cynomolgus monkeys [37]. The intravaginal system was effective in causing a reduction of 263 
systemic E2 by about 30% in the proliferative phase without stimulating the development of ovarian 264 
cysts or the increase of FSH. In fact, one of the major limitation of aromatase inhibitors use in 265 
premenopausal women is the possible stimulation of follicular development, secondary to the rising 266 
of gonadotropin levels, which can lead to the formation of ovarian cysts [38]. To prevent this 267 
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phenomenon, a combination of aromatase inhibitors and a combined oral contraceptive (OC) or 268 
progestin could be advisable.  269 
A multicenter Phase I, randomized controlled trial [39], was conducted to evaluate the 270 
pharmacokinetics, pharmacodynamics, safety and tolerability of intravaginal ring containing three 271 
different dose combinations of AZT and LNG (Treatment A: 1 ring, 500 μg/d ATZ and 20 μg/d 272 
LNG; Treatment B: 1 ring, 1000 μg/d ATZ and 30 μg/d LNG; Treatment C: 2 ring, 1500 μg/d ATZ 273 
and 40 μg/d LNG. The trial was performed on 60 healthy premenopausal women and the treatment 274 
period consisted of 56 days (two cycles of 28 days without ring-free interval). During the study 275 
period the mean size of the largest follicle-like structures was higher in all three treatment arms than 276 
during the pre-treatment cycle; however, changes in the mean size of the cysts were comparable to 277 
those described for low-dose progestin-only OC and generally resolved during the 2-month 278 
treatment period. Serum E2 levels were below 20 pg/ml in both cycles only in the mid- and high-279 
dose groups. All the three combinations of AZT and LNG were well tolerated. To achieve a LNG 280 
systemic exposure similar to that obtained after daily oral administration, the optimal intravaginal 281 
ring LNG delivery rate was 40 pg/ml. The doses selected for AZT to be investigated in Phase 2 282 
studies on patients with endometriosis were 300, 600 and 1050 μg/d. 283 
DISCUSSION 284 
The main potential advantages of the vaginal administration of therapeutics are the reduction of 285 
daily dosages and the continuity of drug release. Moreover, the possibility of extending the interval 286 
between doses represents a favorable option for the patient that can enhance her adherence to the 287 
drug regimen [3]. 288 
 Another advantage of the vaginal route compared to oral administration is the by-passing of 289 
gastrointestinal absorption and thus of the hepatic first-pass effect. Unpredictable factors, like 290 
vomiting or reduced absorbent capacity of the bowel, could interfere with the gastrointestinal 291 
absorption. In addition, both the liver and the gastrointestinal system are accountable for the 292 
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elimination of numerous compounds [40]. For this reason, avoidance of the hepatic first-pass effect 293 
is especially useful for drugs subject to an intense hepatic metabolism. As an example, natural 294 
estrogens, when given orally, are metabolized by the liver for the 95%. Consequently, the 295 
possibility of vaginal drug delivery permits the prescription of lower doses with reduced incidence 296 
of side effects and, at the same time, is able to reach the same pharmacodynamic effect [41]. In fact, 297 
the avoidance of hepatic first pass metabolism with vaginal delivery of estradiol permits the use of a 298 
10- to 20-fold lower dose to obtain the same systemic levels compared with oral administration 299 
[41]. 300 
 An additional advantage of the intravaginal route is its reversibility and easiness of use, 301 
which makes the woman in control of its application. However, at the same time, this represents one 302 
of the major obstacles to overcome. In fact, a large part of the female population perceives the idea 303 
of inserting a drug (ring, tablet or gel) in the vagina as a “foreign body” that can interfere with 304 
personal hygiene or can cause adverse effects on coitus [42]. In addition, as demonstrated by an 305 
online survey in 2004, entitled the International Vagina Dialogue Survey, more than half of the 306 
interviewed didn't know the correct anatomy of the vagina and only 35% were aware of the 307 
possibility of using the vaginal route for drug administration. In this view, the role of gynecologists, 308 
in counseling their patients regarding popular misconceptions about the vagina and the applicability 309 
of this route for drug administration is of primary importance [42]. 310 
 The disadvantages associated with the intravaginal route include the risk of spontaneous 311 
expulsion of vaginal rings, that occasionally goes unnoticed, the possibility of increased local 312 
adverse effects, such as vaginal infection, increased leucorrhea, vaginal discomfort and local 313 
lesions. In a large observational study on the use of the CVR [43] the most commonly reported side 314 
effects were headache (6%), vaginitis (6%) and leucorrhea (5%). Vaginal discomfort and ring-315 
related local events were described in 2% and 4% of the enrolled patients [43]. The withdrawal rate 316 
due to vaginitis and leucorrhea was low (1.3%) [43]. Another clinical trial [44] compared the CVR 317 
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with a COC (EE 30 μg + LNG 150 μg), with a follow-up of 12 months. A high percentage of 318 
women enrolled in the CVR group reported vaginitis and leucorrhea during the study period (11%), 319 
however, only 1% discontinued the CVR for this reason. Fine et al. [45] evaluated the safety and 320 
efficacy of the CVR in 81 women who had undertaken a surgical abortion. The CVR was inserted a 321 
week after the surgical procedure. After one month, 4% of the patients had experienced a bacterial 322 
vaginosis and 2% a Candida infections. Finally, the increased risk of bacterial vaginosis was 323 
supposed also by Archer et al. [46], who reported an improved Nugent score in 40% of vaginal 324 
contraceptive rings users.  325 
 Another field of concern regarding CVR is the fear of feeling the ring during coitus and 326 
during everyday activity. Two large studies [47-48] showed reassuring results, in fact, more than 327 
85% of the participants reported that they did not perceive the ring during sexual intercourses.  328 
The rationale behind the use of local treatments for vaginal endometriosis includes the 329 
above-mentioned advantages of the vaginal route, comprising the avoiding of the hepatic first-pass 330 
effect, the possibility of adopting lower doses than those required for oral administration, the 331 
reduction of side effects. Moreover, a local administration in close proximity to the endometriotic 332 
nodules and plaques could result in higher concentrations of the drug in the surrounding area, with 333 
the potential result of a “target lesion” therapy. Overall, a substantial amelioration of pelvic pain 334 
symptoms associated with endometriosis was observed, particularly of dysmenorrhea.  335 
Several studies have demonstrated that vaginal administration of danazol allows the use of 336 
significantly lower doses than those adopted for the oral route, with serum concentration being 337 
lower than after oral assumption [34, 36]. In fact, low-dose vaginal danazol has been adopted with 338 
positive results in mild-to-moderate endometriosis at a daily dose of 100 mg and 200 mg [27,29,30] 339 
(Table 1), whereas, in most studies, higher oral daily doses (400 to 800 mg) are needed to achieve 340 
positive outcomes on pain symptoms [49-62]. In addition, vaginal danazol has been proven to be 341 
effective for endometriosis-related pain with limited side effects [25-30,34].  342 
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 In addition, an increased expression of aromatase activity has been demonstrated in 343 
endometriosis lesions. This overexpression provokes a hyperestrogenic milieu within the implant 344 
that could favor the progression of the disease [34]. Furthermore, aromatase activity is absent in 345 
normal human endometrium and is increased in endometriosis lesions [63]. Almost all the available 346 
evidence concerning the use of aromatase inhibitors in patients with endometriosis refer to oral 347 
drugs [64-74]. Only a pilot study [6] has evaluated the potential role of vaginal anastrozole on 348 
women with symptomatic rectovaginal endometriosis, with encouraging preliminary results. Given 349 
this background, the use of vaginal drugs with inhibitory activity on this enzyme, like danazol or 350 
aromatase inhibitors, could have a role specifically in the treatment of vaginal endometriosis.    351 
CONCLUSIONS 352 
 Future studies should focus on implementation of the use of the vagina as a drug delivery 353 
modality, in particular in those patients with deep infiltrating and vaginal lesions. In fact, as 354 
demonstrated in previous studies [5,26], vaginal treatments appeared efficacious mostly in women 355 
with rectovaginal lesions, probably due to the higher local concentration of drug obtainable from 356 
direct contact between the drug itself and the lesions located in the posterior fornix.  357 
 Women should be carefully instructed about the correct modality for positioning drugs 358 
intravaginally. In fact, the compounds should be placed at bedtime, deeply into the cranial portion 359 
of the vaginal canal to prevent drug dispersion with subsequent variability of serum levels. 360 
Moreover, the correct placement of vaginal drugs appears crucial particularly in women with DIE, 361 
in order to obtain a high drug concentration near the endometriotic vaginal lesions and avoid 362 
absorption of the compound into the hemorrhoidal and internal pudendal vascular plexuses.  363 
  Ideally, in endometriosis patients’ hormonal drugs should inhibit ovulation. Therefore, in 364 
case aromatase inhibitors are used vaginally, they should be combined with progestins at doses 365 
sufficient to inhibit the hypothalamic-pituitary-ovarian axis.  366 
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The vaginal route represents a partially unexplored route for drug administration, especially 367 
in women with vaginal endometriosis. Transvaginal drug delivery offers several biochemical and 368 
metabolic advantages, beyond its simplicity and reversibility of use.  There is a great need for 369 
further research in this promising field of application of hormonal drugs for the treatment of the 370 
most demanding forms of endometriosis. 371 
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